The Dry Eye Zone

Rebecca's Blog


Drug news: Celtic Therapeutics acquires RX-10045 from Resolvyx

...and Phase III clinical is still supposed to start this half of 2011.

Celtic licenses Resolvyx Pharma dry eye syndrome compound

Celtic Therapeutics has licensed and taken over worldwide rights related to Resolvyx Pharmaceuticals' RX-10045 as a treatment of dry eye syndrome and other ophthalmic conditions.

Resolvyx Pharma has scheduled RX-10045 Phase III randomized, placebo-controlled, multi-center study in 2011.

Under the agreement, Celtic Therapeutics may also license rights to and develop a second Resolvyx compound in a topical formulation for ophthalmic indications.